The Platform Compounders: Biotech’s Best Buy-and-Hold Names
Watch for Inflecting R&D Productivity
This will be a “best ideas only” bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.
The Test I’m Running On Each Name
I’m not giving you every “platform-ish” biotech. I’m filtering for companies where the technology generates candidates more efficiently than the industry baseline, and this efficiency is demonstrated, not claimed.
The marker of a real platform is that each successive program costs less time and money per IND than the last, and targeting a new disease is a matter of redirecting the same primitive rather than starting discovery from scratch.
A genuine platform-expansion compounder needs all four of these, not three: